AMN Healthcare Announces Fourth Quarter and Full Year 2024 Results

Rhea-AI Summary

AMN Healthcare reported Q4 2024 revenue of $735 million, down 10% year-over-year but up 7% from previous quarter. The company posted a Q4 net loss of ($4.90) per share, primarily due to a $222 million non-cash goodwill impairment charge. Adjusted EPS was $0.75.

Key segment performance: Nurse and Allied Solutions revenue was $455 million (down 15% YoY), Physician and Leadership Solutions revenue was $173 million (up 3% YoY), and Technology and Workforce Solutions revenue was $107 million (down 5% YoY).

Full year 2024 results showed consolidated revenue of $2.984 billion, a 21% decrease from 2023. The company reduced debt by $75 million in Q4, bringing full-year repayment to $250 million. Cash flow from operations was $73 million for Q4 and $320 million for the year.

Positive

• Labor disruption revenue of $62 million exceeded guidance by $22 million
• Cash flow from operations strong at $320 million for the year
• Debt reduction of $250 million in 2024
• Locum tenens MSP business showed 20%+ volume increase in second half
• Language services revenue grew 12% year-over-year

Negative

• $222 million non-cash goodwill impairment charge in Q4
• Q4 net loss of ($188 million) or ($4.90) per share
• Full year revenue declined 21% to $2.984 billion
• Travel nurse revenue down 35% year-over-year
• Adjusted EBITDA margin decreased 390 basis points year-over-year

Insights

Financial Analyst

The Q4 2024 results reveal AMN Healthcare's transition challenges in a post-pandemic healthcare staffing market. While the $735 million revenue exceeded expectations, the underlying metrics signal significant structural changes in the business model.

The core travel nurse segment's 35% year-over-year decline reflects the ongoing normalization of healthcare staffing demands. However, the company's ability to generate $62 million in labor disruption revenue demonstrates its operational agility and market position strength. The successful migration of ShiftWise clients to the Flex VMS platform ahead of schedule indicates strong execution in technology transformation initiatives.

The margin profile shows concerning trends, with consolidated gross margin declining 210 basis points year-over-year to 29.8%. This compression stems from pricing normalization across all segments and shifts in revenue mix. The cost management efforts are evident in the SG&A reduction to 21.6% of revenue, though recent accruals for state sales tax audit and professional liability suggest potential operational challenges.

The balance sheet management deserves recognition, with $320 million in operating cash flow for the year enabling $250 million in debt reduction. The 3.0x net leverage ratio provides adequate financial flexibility, though careful monitoring is warranted given the projected revenue declines.

Looking ahead, the 17-20% projected revenue decline for Q1 2025 indicates continued market normalization. The company's strategic focus on technology-enabled solutions and value delivery appears well-aligned with evolving healthcare workforce needs, though execution will be critical in maintaining market leadership during this transition period.

Quarterly revenue of $735 million;
GAAP loss of ($4.90)/share and adjusted EPS of $0.75

DALLAS, Feb. 20, 2025 (GLOBE NEWSWIRE) -- AMN Healthcare Services, Inc. (NYSE: AMN), the leader and innovator in total talent solutions for healthcare organizations across the United States, today announced its fourth quarter and full year 2024 financial results. Financial highlights are as follows:

Dollars in millions, except per share amounts.

	Q4 2024			% Change Q4 2023			Full Year 2024			% Change Full Year 2023
Revenue	$	734.7			(10	%)	$	2,983.8			(21	%)
Gross profit	$	219.0			(16	%)	$	919.4			(26	%)
Net income (loss)	$	(187.5	)		nm		$	(147.0	)		nm
Diluted earnings (loss) per share	$	(4.90	)		nm		$	(3.85	)		nm
Adjusted diluted EPS*	$	0.75			(43	%)	$	3.31			(60	%)
Adjusted EBITDA*	$	75.1			(28	%)	$	340.8			(41	%)

*  See “Non-GAAP Measures” below for a discussion of our use of non-GAAP items and the table entitled “Non-GAAP Reconciliation Tables” for a reconciliation of non-GAAP items.

2024 & Recent Highlights

• Fourth quarter 2024 financial results exceeded our expectations on better results from labor disruption and core nurse and allied staffing revenue.
• The revenue beat included $62 million of labor disruption revenue, which was $22 million more than guidance.
• Excluding labor disruption, Nurse and Allied Solutions and Technology and Workforce Solutions revenue topped the high end of guidance.
• AMN successfully onboarded substantially all of our ShiftWise client base to the ShiftWise Flex VMS platform, ahead of schedule.
• Our strategic accounts recorded net positive client retention for the full year. In locum tenens, our MSP business rebounded with a more than 20% increase in volume over the second half of the year.
• Cash flow from operations was $73 million for the quarter and $320 million for the year.
• We reduced debt by $75 million in the quarter, bringing the full-year repayment to $250 million.

“AMN recorded a solid fourth quarter that outperformed our expectations, and we continue to see a more normalized operating environment compared with the past two years,” said Cary Grace, AMN President and Chief Executive Officer. “Our talented, motivated team continues to make progress in supporting clients’ total workforce needs and unlocking opportunities for growth. We are finding that our heightened emphasis on technology-enabled solutions and delivering value is resonating with both healthcare organizations and healthcare professionals.”

Fourth Quarter 2024 Results

Consolidated revenue for the quarter was $735 million, a 10% decrease over prior year and 7% higher than prior quarter. We reported a net loss of ($188 million), or ($4.90) per diluted share, with the loss resulting from a $222 million non-cash goodwill impairment. This compared with net income of $12 million, or $0.33 per diluted share, in the same quarter last year. Adjusted diluted EPS was $0.75 compared with $1.32 in the year-ago quarter.

Revenue for the Nurse and Allied Solutions segment was $455 million, lower by 15% year over year and up 14% sequentially. We recorded labor disruption revenue of $62 million. Travel nurse revenue was down 35% year over year and 6% sequentially. Allied division revenue declined 9% year over year and increased 6% versus prior quarter.

The Physician and Leadership Solutions segment reported revenue of $173 million, 3% higher year over year and down 4% sequentially. Locum tenens revenue increased 10% year over year, due to the MSDR acquisition, and was down 4% sequentially. Interim leadership revenue was down 11% year over year and 9% sequentially. Search revenue was lower by 32% year over year and up 2% quarter over quarter.

Technology and Workforce Solutions segment revenue was $107 million reflecting a decrease of 5% year over year and 1% sequentially. Language services revenue was $76 million in the quarter, up 12% year over year and 2% compared with the prior quarter. Vendor management systems revenue was $23 million, 26% lower year over year and down 10% sequentially.

Consolidated gross margin was 29.8%, lower by 210 basis points year over year and lower by 120 basis points sequentially. The year-over-year decline in gross margin was primarily driven by lower margin in all three segments. On a sequential basis, gross margin decreased due to lower Nurse and Allied margin and an unfavorable segment mix shift.

SG&A expenses were $159 million or 21.6% of revenue, compared with $185 million, or 22.7% of revenue, in the same quarter last year. SG&A was $150 million, or 21.8% of revenue, in the previous quarter. The year-over-year decrease in SG&A costs was primarily due to cost-containment efforts given lower revenue. The quarter-over-quarter increase was driven primarily by unfavorable accruals for a state sales tax audit and professional liability, and higher labor disruption support costs, partially offset by cost-reduction efforts.

During the fourth quarter, we recorded a non-cash goodwill impairment charge of $222 million related to our Nurse and Allied Solutions and Physician and Leadership Solutions segments. The impairment assessment and related charge was primarily triggered by the decline in the Company’s equity market capitalization.

Loss from operations was ($203 million) compared with income from operations of $34 million in the same quarter last year. Adjusted EBITDA was $75 million, reflecting a year-over-year decrease of 28%. Adjusted EBITDA margin was 10.2%, lower by 250 basis points year over year and a decrease of 50 basis points sequentially.

Full Year 2024 Results

Full year 2024 consolidated revenue was $2.984 billion, a 21% decrease from prior year. Full year net loss was ($147 million), or ($3.85) per diluted share, compared with net income of $211 million, or $5.36 per diluted share, in the prior year. Adjusted diluted EPS was $3.31 compared with $8.21 in 2023.

Nurse and Allied Solutions segment revenue was $1.816 billion, a year-over-year decrease of 31%. The Physician and Leadership Solutions segment recorded revenue of $729 million, 9% higher compared with the prior year driven by the MSDR acquisition. Technology and Workforce Solutions segment revenue was $439 million, 11% lower year over year.

Full year consolidated gross margin was 30.8% compared with 33.0% for the prior year. The drop in gross margin year over year is attributable to a lower gross margins in all segments, partially offset by a favorable change in revenue mix.

Full year consolidated SG&A expenses were $632 million, representing 21.2% of revenue as compared to $756 million, representing 20.0% of revenue, for the prior year. The year-over-year decrease in SG&A expenses was primarily due to lower employee compensation and benefits.

Full year loss from operations was ($103 million) compared with income from operations of $338 million in the prior year. Adjusted EBITDA was $341 million, a year-over-year decrease of 41%. Adjusted EBITDA margin was 11.4%, 390 basis points lower year over year.

At December 31, 2024, cash and cash equivalents totaled $11 million. Cash flow from operations was $73 million for the quarter and $320 million for the full year. Capital expenditures were $16 million in the quarter and $81 million for the year. The Company ended the year with total debt outstanding of $1.060 billion, including a revolving credit balance of $210 million, and a net leverage ratio of 3.0 to 1. The Company reduced its revolver balance by $250 million in 2024.

First Quarter 2025 Outlook

Metric	Guidance*
Consolidated revenue	$660 - $680 million
Gross margin	28.1% - 28.6%
SG&A as percentage of revenue	22.2% - 22.7%
Operating margin	(0.3%) - 0.4%
Adjusted EBITDA margin	7.7% - 8.2%
*Note: Guidance percentage metrics are approximate.  For a reconciliation of adjusted EBITDA margin, see the table entitled “Reconciliation of Guidance Operating Margin to Guidance Adjusted EBITDA Margin” below.

Consolidated revenue in the first quarter of 2025 is projected to be 17-20% lower than the year-ago period. Nurse and Allied Solutions segment revenue is expected to be 22-25% lower than prior year, and guidance assumes $24 million of labor disruption revenue. We expect Physician and Leadership Solutions segment revenue in the first quarter to be 9-11% lower year over year. Technology and Workforce Solutions segment revenue is projected to be down 8-10% year over year.

Other first quarter estimates include depreciation expense of $19 million, depreciation in cost of services of $2 million, non-cash amortization expense of $20 million, stock-based compensation expense of $9 million, interest expense of $12 million, integration and other expenses of $3 million, an adjusted tax rate of 26%, and 38.4 million weighted average diluted shares.

Conference Call on February 20, 2025

AMN Healthcare Services, Inc. (NYSE: AMN), the leader and innovator in total talent solutions for healthcare, will host a conference call to discuss its fourth quarter and full year 2024 financial results and first quarter 2025 outlook on Thursday, February 20, 2025, at 5:00 p.m. Eastern Time. A live webcast of the call can be accessed through this webcast link, which also will be available at AMN Healthcare’s investor relations website. Interested parties may participate live via telephone by registering at this conference call link. Please follow the link and register with a valid e-mail address. A PIN will be provided to you with dial-in instructions. If you lose track of these details, please re-register at the conference call link above.

About AMN Healthcare

AMN Healthcare is the leader and innovator in total talent solutions for healthcare organizations across the United States. The Company provides access to the most comprehensive network of quality healthcare professionals through its innovative recruitment strategies and breadth of career opportunities. With insights and expertise, AMN Healthcare helps providers optimize their workforce to successfully reduce complexity, increase efficiency and improve patient outcomes. AMN total talent solutions include managed services programs, clinical and interim healthcare leaders, temporary staffing, direct hire and retained search solutions, vendor management systems, recruitment process outsourcing, predictive modeling, language interpretation services, revenue cycle solutions, credentialing, and other services. Clients include acute-care hospitals, community health centers and clinics, physician practice groups, retail and urgent care centers, home health facilities, schools, and many other healthcare settings. AMN Healthcare is committed to fostering and maintaining a diverse team that reflects the communities we serve. Our commitment to the inclusion of many different backgrounds, experiences and perspectives enables our innovation and leadership in the healthcare services industry.

The Company’s common stock is listed on the New York Stock Exchange under the symbol “AMN.” For more information about AMN Healthcare, visit www.amnhealthcare.com, where the Company posts news releases, investor presentations, webcasts, SEC filings and other material information. The Company also utilizes email alerts and Really Simple Syndication (“RSS”) as routine channels to supplement distribution of this information. To register for email alerts and RSS, visit http://ir.amnhealthcare.com.

Non-GAAP Measures

This earnings release and the non-GAAP reconciliation tables included with the earnings release contain certain non-GAAP financial information, which the Company provides as additional information, and not as an alternative, to the Company’s condensed consolidated financial statements presented in accordance with GAAP. These non-GAAP financial measures include (1) adjusted EBITDA, (2) adjusted EBITDA margin, (3) adjusted net income, and (4) adjusted diluted EPS. The Company provides such non-GAAP financial measures because management believes that they are useful both to management and investors as a supplement, and not as a substitute, when evaluating the Company’s operating performance. Additionally, management believes that adjusted EBITDA, adjusted EBITDA margin, adjusted net income, and adjusted diluted EPS serve as industry-wide financial measures. The Company uses adjusted EBITDA for making financial decisions, allocating resources and for determining certain incentive compensation objectives. The non-GAAP measures in this release are not in accordance with, or an alternative to, GAAP measures and may be different from non-GAAP measures, or may be calculated differently than other similarly titled non-GAAP measures, reported by other companies. They should not be used in isolation to evaluate the Company’s performance.  A reconciliation of non-GAAP measures identified in this release, along with further detail about the use and limitations of certain of these non-GAAP measures, may be found below in the table entitled “Non-GAAP Reconciliation Tables” under the caption entitled “Reconciliation of Non-GAAP Items” and the footnotes thereto or on the Company’s website at https://ir.amnhealthcare.com/financials/quarterly-results/default.aspx. Additionally, from time to time, additional information regarding non-GAAP financial measures, including pro forma measures, may be made available on the Company’s website.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements include, among others, statements concerning client retention, whether our MSP business will continue to rebound, whether our operating environment will continue to normalize, our ability to make progress in supporting clients' total workforce needs and unlock opportunities for growth, whether our emphasis on technology-enabled solutions and delivering value will resonate with healthcare organizations and healthcare professionals, demand for our services, and our outlook for 2025 consolidated revenue, gross margin, SG&A expenses as a percentage of revenue, operating margin, adjusted EBITDA margin, first quarter year-over-year revenue performance for each of our Nurse and Allied, Physician and Leadership, and Technology and Workforce Solutions reporting segments, labor disruption revenue, depreciation expense, depreciation in cost of services, non-cash amortization expense, stock-based compensation expense, interest expense, integration and other expenses, adjusted tax rate, amortization expense and weighted average diluted shares. In addition, the financial results set forth in this press release reflect the Company’s current preliminary financial results prior to completion of the Company’s audit process and are subject to change. The Company bases these forward-looking statements on its current expectations, estimates and projections about future events and the industry in which it operates using information currently available to it. Forward-looking statements are identified by words such as “believe,” “anticipate,” “expect,” “intend,” “plan,” “will,” “may,” “estimates,” variations of such words and other similar expressions. In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances are forward-looking statements. Actual results could differ materially from those discussed in, or implied by, these forward-looking statements as a result of a variety of factors, including consummating and incorporating acquisitions into our business, complying with extensive federal and state regulations related to the conduct of our operations, and continuing to recruit and retain sufficient quality healthcare professionals at reasonable costs. 

The targets and expectations noted in this release depend upon, among other factors, (i) the duration of the period that hospitals and other healthcare entities decrease their utilization of temporary employees, physicians, leaders and other workforce technology applications, (ii) the ability of our clients to increase the efficiency and effectiveness of their staffing management and recruiting efforts, through predictive analytics, online recruiting, telemedicine or otherwise, and successfully hire and retain permanent staff, (iii) the extent to which the extent and duration challenging economic times will cause an increase in under- and uninsured patients and a corresponding reduction in overall healthcare utilization and demand for our services, (iv) our ability to effectively address client demand by attracting and placing nurses and other clinicians, (v) our ability to anticipate and quickly respond to changing marketplace conditions, such as alternative modes of healthcare delivery, reimbursement, or client needs, (vi) the effects of the COVID-19 pandemic or any future pandemic or health crisis on our business, financial condition and results of operation, (vii) our ability to manage the pricing impact that consolidation of healthcare delivery organizations may have on our business, (viii) the extent to which challenging economic times will have on the financial condition and cash flow of many hospitals and healthcare systems such that it impairs their ability to make payments to us, timely or otherwise, for services rendered, (ix) our ability to recruit and retain sufficient quality healthcare professionals at reasonable costs (x) our ability to develop and evolve our current technology offerings and capabilities and implement new infrastructure and technology systems to optimize our operating results and manage our business effectively, (xiii) our ability to comply with extensive and complex federal and state laws and regulations related to the conduct of our operations, costs and payment for services and payment for referrals as well as laws regarding employment practices, (xi) security breaches and cybersecurity incidents, including ransomware, that could compromise our information and systems and (xi) our ability to consummate and effectively incorporate acquisitions into our business.

For a discussion of additional risk factors and a more complete discussion of some of the cautionary statements noted above that could cause actual results to differ from those implied by the forward-looking statements contained in this press release, please refer to “Risk Factors” under Item 1A of our most recent Annual Report on Form 10-K for the year ended December 31, 2023, our subsequent Quarterly Reports on Form 10-Q and our Current Reports on Form 8-K. Be advised that developments subsequent to this press release are likely to cause these statements to become outdated and the Company is under no obligation (and expressly disclaims any such obligation) to update or revise any forward-looking statements whether as a result of new information, future events, or otherwise.

Contact:
Randle Reece
Senior Director, Investor Relations
866.861.3229

AMN Healthcare Services, Inc. Condensed Consolidated Statements of Comprehensive Income (Loss) (in thousands, except per share amounts) (unaudited)
	Three Months Ended												Twelve Months Ended
	December 31,								Sept 30,				December 31,
		2024				2023				2024				2024				2023
Revenue	$	734,709			$	818,269			$	687,509			$	2,983,781			$	3,789,254
Cost of revenue		515,721				557,321				474,454				2,064,405				2,539,673
Gross profit		218,988				260,948				213,055				919,376				1,249,581
Gross margin		29.8	%			31.9	%			31.0	%			30.8	%			33.0	%
Operating expenses:
Selling, general and administrative (SG&A)		158,922				185,463				149,681				632,489				756,238
SG&A as a % of revenue		21.6	%			22.7	%			21.8	%			21.2	%			20.0	%
Depreciation and amortization (exclusive of depreciation included in cost of revenue)		40,161				41,315				41,122				167,103				154,914
Goodwill impairment losses		222,457				—				—				222,457				—
Total operating expenses		421,540				226,778				190,803				1,022,049				911,152
Income (loss) from operations		(202,552	)			34,170				22,252				(102,673	)			338,429
Operating margin (1)		(27.6	)%			4.2	%			3.2	%			(3.4	)%			8.9	%
Interest expense, net, and other (2)		23,114				20,165				14,444				69,901				54,140
Income (loss) before income taxes		(225,666	)			14,005				7,808				(172,574	)			284,289
Income tax expense (benefit)		(38,133	)			1,516				819				(25,595	)			73,610
Net income (loss)	$	(187,533	)		$	12,489			$	6,989			$	(146,979	)		$	210,679
Net income (loss) as a % of revenue		(25.5	)%			1.5	%			1.0	%			(4.9	)%			5.6	%
Other comprehensive income:
Unrealized gains on available-for-sale securities, net, and other		45				187				101				412				516
Other comprehensive income		45				187				101				412				516
Comprehensive income (loss)	$	(187,488	)		$	12,676			$	7,090			$	(146,567	)		$	211,195
Net income (loss) per common share
Basic	$	(4.90	)		$	0.33			$	0.18			$	(3.85	)		$	5.38
Diluted	$	(4.90	)		$	0.33			$	0.18			$	(3.85	)		$	5.36
Weighted average common shares outstanding:
Basic		38,263				38,063				38,200				38,188				39,173
Diluted		38,263				38,167				38,287				38,188				39,341

AMN Healthcare Services, Inc. Condensed Consolidated Balance Sheets (dollars in thousands) (unaudited)
	December 31, 2024				September 30, 2024				December 31, 2023
Assets
Current assets:
Cash and cash equivalents	$	10,649			$	30,550			$	32,935
Accounts receivable, net		437,817				451,062				623,488
Accounts receivable, subcontractor		70,481				68,566				117,703
Prepaid and other current assets		75,968				62,088				67,559
Total current assets		594,915				612,266				841,685
Restricted cash, cash equivalents and investments		71,840				72,167				68,845
Fixed assets, net		186,270				196,902				191,385
Other assets		258,053				267,266				236,796
Deferred income taxes, net		25,829				—				—
Goodwill		897,456				1,116,815				1,111,549
Intangible assets, net		381,364				402,400				474,134
Total assets	$	2,415,727			$	2,667,816			$	2,924,394
Liabilities and stockholders’ equity
Current liabilities:
Accounts payable and accrued expenses	$	184,311			$	213,206			$	343,847
Accrued compensation and benefits		287,544				281,683				278,536
Other current liabilities		73,930				23,657				33,738
Total current liabilities		545,785				518,546				656,121
Revolving credit facility		210,000				285,000				460,000
Notes payable, net		845,872				845,576				844,688
Deferred income taxes, net		—				17,270				23,350
Other long-term liabilities		107,450				110,759				108,979
Total liabilities		1,709,107				1,777,151				2,093,138
Commitments and contingencies
Stockholders’ equity:		706,620				890,665				831,256
Total liabilities and stockholders’ equity	$	2,415,727			$	2,667,816			$	2,924,394

AMN Healthcare Services, Inc. Summary Condensed Consolidated Statements of Cash Flows (dollars in thousands) (unaudited)
	Three Months Ended												Twelve Months Ended
	December 31,								Sept 30,				December 31,
		2024				2023				2024				2024				2023
Net cash provided by (used in) operating activities	$	72,814			$	(41,130	)		$	66,703			$	320,418			$	372,165
Net cash used in investing activities		(14,203	)			(323,731	)			(22,004	)			(79,938	)			(412,493	)
Net cash provided by (used in) financing activities		(79,898	)			363,495				(60,469	)			(259,448	)			10,729
Net decrease in cash, cash equivalents and restricted cash		(21,287	)			(1,366	)			(15,770	)			(18,968	)			(29,599	)
Cash, cash equivalents and restricted cash at beginning of period		110,592				109,639				126,362				108,273				137,872
Cash, cash equivalents and restricted cash at end of period	$	89,305			$	108,273			$	110,592			$	89,305			$	108,273

AMN Healthcare Services, Inc. Non-GAAP Reconciliation Tables (dollars in thousands, except per share data) (unaudited)
	Three Months Ended												Twelve Months Ended
	December 31,								Sept 30,				December 31,
		2024				2023				2024				2024				2023
Reconciliation of Non-GAAP Items:
Net income (loss)	$	(187,533	)		$	12,489			$	6,989			$	(146,979	)		$	210,679
Income tax expense (benefit)		(38,133	)			1,516				819				(25,595	)			73,610
Income (loss) before income taxes		(225,666	)			14,005				7,808				(172,574	)			284,289
Interest expense, net, and other (2)		23,114				20,165				14,444				69,901				54,140
Income (loss) from operations		(202,552	)			34,170				22,252				(102,673	)			338,429
Depreciation and amortization		40,161				41,315				41,122				167,103				154,914
Depreciation (included in cost of revenue) (3)		1,313				1,817				1,928				6,676				6,013
Goodwill impairment losses		222,457				—				—				222,457				—
Share-based compensation		3,666				2,578				5,555				23,317				18,020
Acquisition, integration, and other costs (4)		10,078				24,124				3,017				23,870				40,740
Legal settlement accrual changes (5)		—				—				—				—				21,000
Adjusted EBITDA (6)	$	75,123			$	104,004			$	73,874			$	340,750			$	579,116
Adjusted EBITDA margin (7)		10.2	%			12.7	%			10.7	%			11.4	%			15.3	%
Net income (loss)	$	(187,533	)		$	12,489			$	6,989			$	(146,979	)		$	210,679
Adjustments:
Amortization of intangible assets		21,036				23,416				22,104				92,770				89,756
Acquisition, integration, and other costs (4)		10,078				24,124				3,017				23,870				40,740
Goodwill impairment losses		222,457				—				—				222,457				—
Legal settlement accrual changes (5)		—				—				—				—				21,000
Fair value changes of equity investments and instruments (2)		9,730				6,701				—				9,730				6,701
Cumulative effect of change in accounting principle (8)		—				—				—				—				2,974
Tax effect on above adjustments		(47,100	)			(14,103	)			(6,532	)			(69,337	)			(41,905	)
Tax effect of COLI fair value changes (9)		(290	)			(3,446	)			(2,530	)			(6,464	)			(5,770	)
Tax deficiencies (benefits) related to equity awards and ESPP (10)		465				1,174				206				610				(1,172	)
Adjusted net income (11)	$	28,843			$	50,355			$	23,254			$	126,657			$	323,003
GAAP diluted net income (loss) per share (EPS)	$	(4.90	)		$	0.33			$	0.18			$	(3.85	)		$	5.36
Adjustments		5.65				0.99				0.43				7.16				2.85
Adjusted diluted EPS (12) (13)	$	0.75			$	1.32			$	0.61			$	3.31			$	8.21

AMN Healthcare Services, Inc. Supplemental Segment Financial and Operating Data (dollars in thousands, except operating data) (unaudited)
	Three Months Ended												Twelve Months Ended
	December 31,								Sept 30,				December 31,
		2024				2023				2024				2024				2023
Revenue
Nurse and allied solutions	$	454,654			$	537,588			$	399,368			$	1,815,718			$	2,624,509
Physician and leadership solutions		173,141				168,161				180,605				728,608				669,701
Technology and workforce solutions		106,914				112,520				107,536				439,455				495,044
	$	734,709			$	818,269			$	687,509			$	2,983,781			$	3,789,254
Segment operating income (14)
Nurse and allied solutions	$	38,932			$	62,838			$	35,110			$	173,591			$	362,158
Physician and leadership solutions		17,032				21,801				18,134				79,049				94,966
Technology and workforce solutions		40,278				41,439				41,948				173,755				214,736
		96,242				126,078				95,192				426,395				671,860
Unallocated corporate overhead (15)		21,119				22,074				21,318				85,645				92,744
Adjusted EBITDA (6)	$	75,123			$	104,004			$	73,874			$	340,750			$	579,116
Gross Margin
Nurse and allied solutions		23.8	%			25.5	%			25.0	%			24.5	%			26.4	%
Physician and leadership solutions		28.5	%			33.3	%			28.3	%			29.7	%			34.3	%
Technology and workforce solutions		57.3	%			60.5	%			57.9	%			58.9	%			66.2	%
Operating Data:
Nurse and allied solutions
Average travelers on assignment (16)		9,206				11,869				9,176				10,052				13,144
Physician and leadership solutions
Days filled (17)		51,641				49,645				55,315				220,045				192,502
Revenue per day filled (18)	$	2,646			$	2,491			$	2,562			$	2,574			$	2,415

	December 31,				September 30,
	2024		2023		2024
Leverage ratio (19)	3.0		2.2		2.8

AMN Healthcare Services, Inc. Additional Supplemental Non-GAAP Disclosures Reconciliation of Guidance Operating Margin to Guidance Adjusted EBITDA Margin (unaudited)
	Three Months Ended
	March 31, 2025
	Low(20)				High(20)
Operating margin		(0.3	)%			0.4	%
Depreciation and amortization (total)		6.2	%			6.0	%
EBITDA margin		5.9	%			6.4	%
Share-based compensation		1.4	%			1.4	%
Acquisition, integration, and other costs		0.4	%			0.4	%
Adjusted EBITDA margin		7.7	%			8.2	%

(1) Operating margin represents income (loss) from operations divided by revenue.
(2) Changes in the fair value of equity investments and instruments are recognized in interest expense, net, and other. Since the changes in fair value are unrelated to the Company’s operating performance, we exclude the impact from the calculations of adjusted net income and adjusted diluted EPS.
(3) A portion of depreciation expense for AMN Language Services is included in cost of revenue. We exclude the impact of depreciation included in cost of revenue from the calculation of adjusted EBITDA.
(4) Acquisition, integration, and other costs include acquisition and integration costs, net changes in the fair value of contingent consideration liabilities for recently acquired companies, certain legal expenses, restructuring expenses and other costs associated with exit or disposal activities, and certain nonrecurring expenses, which we exclude from the calculation of adjusted EBITDA, adjusted net income, and adjusted diluted EPS because we believe that these expenses are not indicative of the Company’s operating performance. For the three and twelve months ended December 31, 2024, acquisition and integration costs were approximately $0.4 million and $2.2 million, respectively, expenses related to the closures of certain office leases were approximately $0.5 million and $2.3 million, respectively, restructuring expenses and other costs associated with exit or disposal activities were approximately $0.4 million and $6.7 million, respectively, and other expenses were approximately $8.8 million and $14.1 million, respectively. Included in other expenses was an immaterial out-of-period adjustment of $7.3 million related to a revenue-based state tax audit. Certain legal expenses were approximately $1.0 million for the twelve months ended December 31, 2024. Additionally, the aforementioned costs for the twelve months ended December 31, 2024 were partially offset by an immaterial out-of-period adjustment of $2.4 million related to acquisition-related costs incurred in connection with the acquisition of MSDR. For the three and twelve months ended December 31, 2023, acquisition and integration costs were approximately $10.4 million and $13.7 million, respectively, expenses related to the closures of certain office leases were approximately $1.1 million and $4.8 million, respectively, certain legal expenses were approximately $(0.1) million and $2.1 million, respectively, restructuring expenses and other costs associated with exit or disposal activities were approximately $10.2 million and $13.9 million, respectively, and other expenses were approximately $2.5 million and $3.7 million, respectively. Additionally, acquisition, integration, and other costs for the twelve months  ended December 31, 2023 included increases in contingent consideration liabilities for recently acquired companies of approximately $2.4 million.
(5) During the year ended December 31, 2023, the Company recorded an increase to its legal accrual for a wage and hour claim in connection with reaching an agreement to settle the matter in its entirety. Since the settlement is largely unrelated to the Company’s operating performance for the year ended December 31, 2023, we excluded its impact in the calculations of adjusted EBITDA, adjusted net income, and adjusted diluted EPS.
(6) Adjusted EBITDA represents net income (loss) plus interest expense (net of interest income) and other, income tax expense (benefit), depreciation and amortization, depreciation (included in cost of revenue), acquisition, integration, and other costs, restructuring expenses, certain legal expenses, share-based compensation and goodwill impairment losses. Management believes that adjusted EBITDA provides an effective measure of the Company’s results, as it excludes certain items that management believes are not indicative of the Company’s operating performance. Adjusted EBITDA is not intended to represent cash flows for the period, nor has it been presented as an alternative to income (loss) from operations or net income (loss) as an indicator of operating performance. Although management believes that some of the items excluded from adjusted EBITDA are not indicative of the Company’s operating performance, these items do impact the consolidated statements of comprehensive income (loss), and management therefore utilizes adjusted EBITDA as an operating performance measure in conjunction with GAAP measures such as net income (loss).
(7) Adjusted EBITDA margin represents adjusted EBITDA divided by revenue.
(8) As a result of a change in accounting principle on January 1, 2023 related to forfeitures of share-based awards, the Company recognized the cumulative effect of the change in share-based compensation expense during the three months ended March 31, 2023. The cumulative effect of the change in accounting principle is immaterial to prior periods and, therefore, was recognized in the period of the change. Since the cumulative effect is unrelated to the Company’s operating performance for the year ended December 31, 2023, we excluded its impact in the calculation of adjusted net income and adjusted diluted EPS.
(9) The Company records net tax expense (benefit) related to the income tax treatment of the fair value changes in the cash surrender value of its company owned life insurance. Since this change in fair value is unrelated to the Company’s operating performance, we excluded the impact on adjusted net income and adjusted diluted EPS.
(10) The consolidated effective tax rate is affected by the recording of tax benefits and tax deficiencies relating to equity awards vested during the period and tax benefits recognized for disqualifying dispositions related to our employee stock purchase plan (“ESPP”). The magnitude of the impact of tax benefits and tax deficiencies generated in the future related to equity awards and ESPP is dependent upon the Company’s future grants of share-based compensation, the Company’s future stock price on the date awards vest in relation to the fair value of the awards on the grant date, the Company’s future stock price on either the ESPP’s offering date or purchase date, whichever is lower, and the length of time the shares issued under the ESPP are held by employees. Since these tax benefits and tax deficiencies are largely unrelated to our income (loss) before taxes and are unrepresentative of our normal effective tax rate, we excluded their impact in the calculations of adjusted net income and adjusted diluted EPS.
(11) Adjusted net income represents GAAP net income (loss) excluding the impact of the (A) amortization of intangible assets, (B) acquisition, integration, and other costs, (C) goodwill impairment losses, (D) certain legal expenses, (E) changes in fair value of equity investments and instruments, (F) deferred financing related costs, (G) tax effect, if any, of the foregoing adjustments, (H) tax benefits and tax deficiencies relating to equity awards vested and ESPP, (I) net tax expense (benefit) related to the income tax treatment of fair value changes in the cash surrender value of its company owned life insurance, and (J) restructuring tax benefits. Management included this non-GAAP measure to provide investors and prospective investors with an alternative method for assessing the Company’s operating results in a manner that is focused on its operating performance and to provide a more consistent basis for comparison between periods. However, investors and prospective investors should note that this non-GAAP measure involves judgment by management (in particular, judgment as to what is classified as a special item to be excluded in the calculation of adjusted net income). Although management believes the items in the calculation of adjusted net income are not indicative of the Company’s operating performance, these items do impact the consolidated statements of comprehensive income (loss), and management therefore utilizes adjusted net income as an operating performance measure in conjunction with GAAP measures such as GAAP net income (loss).
(12) Adjusted diluted EPS represents adjusted net income divided by diluted weighted average common shares outstanding. Management included this non-GAAP measure to provide investors and prospective investors with an alternative method for assessing the Company’s operating results in a manner that is focused on its operating performance and to provide a more consistent basis for comparison between periods. However, investors and prospective investors should note that this non-GAAP measure involves judgment by management (in particular, judgment as to what is classified as a special item to be excluded in the calculation of adjusted net income). Although management believes the items in the calculation of adjusted net income are not indicative of the Company’s operating performance, these items do impact the consolidated statements of comprehensive income (loss), and management therefore utilizes adjusted diluted EPS as an operating performance measure in conjunction with GAAP measures such as GAAP diluted EPS.
(13) As GAAP net loss is reported for the three and twelve months ended December 31, 2024, basic weighted average common shares outstanding was used to calculate GAAP diluted EPS for both periods because the dilutive potential common shares have an anti-dilutive effect (i.e., result in a lower loss per share). As adjusted net income is reported for the three and twelve months ended December 31, 2024, diluted weighted average common shares outstanding (including dilutive potential common shares) of 38,329 and 38,273, respectively, were used to calculate adjusted diluted EPS.
(14) Segment operating income represents net income (loss) plus interest expense (net of interest income) and other, income tax expense (benefit), depreciation and amortization, depreciation (included in cost of revenue), unallocated corporate overhead, acquisition, integration, and other costs, legal settlement accrual changes, share-based compensation and goodwill impairment losses.
(15) Unallocated corporate overhead (as presented in the tables above) consists of unallocated corporate overhead (as reflected in our quarterly and annual financial statements filed with the SEC) less acquisition, integration, and other costs and legal settlement accrual changes.
(16) Average travelers on assignment represents the average number of nurse and allied healthcare professionals on assignment during the period presented. The average travelers on assignment for the three months ended September 30, 2024 was understated in the Company’s third quarter 2024 press release (exhibit 99.1 of the Company’s Current Report on Form 8-K filed on November 7, 2024) due to an administrative error. The correct average travelers on assignment is 9,176, not 9,151, as previously reported.
(17) Days filled is calculated by dividing the locum tenens hours filled during the period by eight hours.
(18) Revenue per day filled represents revenue of the Company’s locum tenens business divided by days filled for the period presented.
(19) Leverage ratio represents the ratio of the consolidated funded indebtedness (as calculated per the Company’s credit agreement) at the end of the subject period to the consolidated adjusted EBITDA (as calculated per the Company’s credit agreement) for the twelve-month period ended at the end of the subject period.
(20) Guidance percentage metrics are approximate.

FAQ

What caused AMN Healthcare's Q4 2024 net loss?

AMN Healthcare's Q4 2024 net loss was primarily due to a $222 million non-cash goodwill impairment charge related to their Nurse and Allied Solutions and Physician and Leadership Solutions segments.

How much debt did AMN Healthcare pay down in 2024?

AMN Healthcare reduced its debt by $250 million in 2024, including $75 million in Q4.

What is AMN's revenue guidance for Q1 2025?

AMN projects Q1 2025 consolidated revenue to be 17-20% lower than the year-ago period, with Nurse and Allied Solutions expected to be down 22-25%.

How did AMN's labor disruption revenue perform in Q4 2024?

AMN's labor disruption revenue was $62 million in Q4 2024, exceeding guidance by $22 million.